These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25658136)

  • 1. Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N-(4-anilinoquinazolin-6-yl) acrylamide.
    Capoferri L; Lodola A; Rivara S; Mor M
    J Chem Inf Model; 2015 Mar; 55(3):589-99. PubMed ID: 25658136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
    Carmi C; Cavazzoni A; Vezzosi S; Bordi F; Vacondio F; Silva C; Rivara S; Lodola A; Alfieri RR; La Monica S; Galetti M; Ardizzoni A; Petronini PG; Mor M
    J Med Chem; 2010 Mar; 53(5):2038-50. PubMed ID: 20151670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
    Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.
    Carmi C; Galvani E; Vacondio F; Rivara S; Lodola A; Russo S; Aiello S; Bordi F; Costantino G; Cavazzoni A; Alfieri RR; Ardizzoni A; Petronini PG; Mor M
    J Med Chem; 2012 Mar; 55(5):2251-64. PubMed ID: 22280453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QM/MM Simulations of Afatinib-EGFR Addition: The Role of β-Dimethylaminomethyl Substitution.
    Ma S; Patel H; Peeples CA; Shen J
    J Chem Theory Comput; 2024 Jul; 20(13):5528-5538. PubMed ID: 38877999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.
    Callegari D; Ranaghan KE; Woods CJ; Minari R; Tiseo M; Mor M; Mulholland AJ; Lodola A
    Chem Sci; 2018 Mar; 9(10):2740-2749. PubMed ID: 29732058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QM/MM modelling of ketosteroid isomerase reactivity indicates that active site closure is integral to catalysis.
    van der Kamp MW; Chaudret R; Mulholland AJ
    FEBS J; 2013 Jul; 280(13):3120-31. PubMed ID: 23356661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
    Engel J; Richters A; Getlik M; Tomassi S; Keul M; Termathe M; Lategahn J; Becker C; Mayer-Wrangowski S; Grütter C; Uhlenbrock N; Krüll J; Schaumann N; Eppmann S; Kibies P; Hoffgaard F; Heil J; Menninger S; Ortiz-Cuaran S; Heuckmann JM; Tinnefeld V; Zahedi RP; Sos ML; Schultz-Fademrecht C; Thomas RK; Kast SM; Rauh D
    J Med Chem; 2015 Sep; 58(17):6844-63. PubMed ID: 26275028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
    Vacondio F; Carmi C; Galvani E; Bassi M; Silva C; Lodola A; Rivara S; Cavazzoni A; Alfieri RR; Petronini PG; Mor M
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5290-4. PubMed ID: 23988354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivities of acrylamide warheads toward cysteine targets: a QM/ML approach to covalent inhibitor design.
    Danilack AD; Dickson CJ; Soylu C; Fortunato M; Rodde S; Munkler H; Hornak V; Duca JS
    J Comput Aided Mol Des; 2024 May; 38(1):21. PubMed ID: 38693331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.
    Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
    Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
    Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QM/MM simulations of EFGR with afatinib reveal the role of the
    Ma S; Patel H; Peeples CA; Shen J
    bioRxiv; 2024 May; ():. PubMed ID: 38766221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QM/MM simulations of amyloid-β 42 degradation by IDE in the presence and absence of ATP.
    da Cruz CH; Seabra GM
    J Chem Inf Model; 2015 Jan; 55(1):72-83. PubMed ID: 25539133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.